

CHANGING THE WAY THE WORLD BREATHES

RHINOMED – BIO2015

Safe Harbour

This presentation contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause the actual results, performance or achievements of Rhinomed Ltd to be materially different from the statements in this presentation. Actual results could differ materially depending on factors such as the availability of resources, the results of clinical studies, the timing and effects of regulatory actions, the strength of competition and the effectiveness of the Company's patent protection.

The Breakfast @ BIO event in Philadelphia on June 17 (the "Reception") is a gathering for purposes of business networking and is intended for general information only and does not constitute any type of advice, financial, business, legal or otherwise. Independent Investment Research makes no representations or warranties of any kind, express or implied, as to the content expressed in any presentations or information given, or as to the correctness, accuracy, reliability or otherwise of such presentations or information. In no event shall Independent Investment Research or any of its partners, directors, officers, employees, agents or affiliates be liable, directly or indirectly, under any theory of law (securities, contract, tort, negligence or otherwise), to you or anyone else, for any claims, losses or damages, direct, indirect, special, incidental, punitive or consequential, resulting from or occasioned by your attendance at the Reception or use of or reliance on any of the content or materials given or presented at the Reception. None of the presentations, discussions or information disseminated at the Reception should be construed as investment advice, as any recommendation of a transaction or business opportunity, or as an offer to buy or sell any security or other financial instrument. Independent Investment Research is not soliciting any action based upon it

WHO IS RHINOMED?

- A nasal and respiratory medical technology company based in Melbourne, Australia.
- Rhinomed develops, markets and partners its internal nasal technology platform into multiple form factors - internal nasal devices.
- A platform technology covered by a family of over 60 patents
- Focus is unmet needs in
 - sports & exercise,
 - sleep (snoring, sleep quality and sleep apnea,
 - wellness and,
 - drug delivery.

MANAGEMENT	BOARD
Michael Johnson, CEO & Managing Director	Martin Rogers, Chairman
Justine Heath, COO/CFO	Brent Scrimshaw, Non Exec Director
Dr Mitchell Anderson, CMO	Dr Eric Knight, Non Exec Director

DEVELOPING A PLATFORM TECHNOLOGY

	Preclinical	Phase 1			Regulatory	In Market
OTC Dyspnoea in Sport and Exercise						<ul style="list-style-type: none">• FDA• CE Mark• Early Revenues
User Trial						
OTC Snoring and Sleep Quality						<ul style="list-style-type: none">• FDA• CE Mark• Early Revenues
	Preclinical	Phase 1	Phase 2	Phase 3	Regulatory	In Market
Sleep Apnea						
Drug Delivery – Acute Migraine (sumatriptan)		Seeking to partner				
Hayfever - OTC						
Congestion - OTC						
Anxiety -OTC						

INTRODUCING A NOVEL NASAL TECHNOLOGY PLATFORM



BUY NOW
www.theturbine.com



CHRIS FROOME – 2013 WINNER OF THE TOUR DE FRANCE

DELIVERING AN END TO END SLEEP CATEGORY SOLUTION



A PATENTED CATEGORY DEFINING BRANDED TECHNOLOGY



RAPIDLY GAINING CUSTOMER SUPPORT



“I’ve snored since I was five and over the years have tried pretty much everything. I’ve even considered surgery. The sound often wakes me up and most nights my husband Colin has to retreat to the spare room.

I’ve tried Rhinomed’s product Mute a few times now and haven’t woken myself up once. My husband says my snoring is much reduced and much quieter, so I’m going to keep using it.”

Jenny Chapman – April
2015

The UK has the loudest snorer ever recorded at 111 decibels - 8 decibels louder than a low flying jet

Jenny Chapman in 2009 courtesy of The Telegraph

<http://www.telegraph.co.uk/news/health/news/6342113/Britains-loudest-snorer.html>

WITH PROVEN EFFICACY

"I'm concerned about my own snoring" - **75%**

"I've woken myself up" - **55%**

"My partner feels sleep deprived because of my snoring" - **46%**

"I'm concerned about my personal relationship with my partner" - **27%**


MUTE WORKS - IN HOME USER PRODUCT TRIAL RESULTS



OF THE SUBJECTS
REPORTED A
**REDUCTION
IN SNORING**

2014 USER TRIAL N=236 INCLUDES
5 DAYS OF CONTINUAL USE

MUTE USERS EXPERIENCED IMPROVEMENTS ACROSS THE BOARD



Mute User trial. N=236. 5 Day in-home user trial. November 2014

SLEEP APNEA HAS A BILLION DOLLAR PROBLEM



- **70% of patients have moderate sleep apnea¹**
- **80% of those with apnea remain undiagnosed²**
- **the gold standard has a < 38% compliance rate³**
- **high entry cost for treatment.**
- **few alternative treatments**
- **all highly invasive and with low acceptance.**

EXISTING THERAPIES ARE STRUGGLING TO ACQUIRE OR RETAIN PATIENTS

1. Wisconsin Sleep Cohort Study 2. Resmed 3. Adherence to continuous positive airway pressure therapy: the challenge to effective treatment. Weaver TE, Grunstein RR SO Proc Am Thorac Soc. 2008;5(2):173


INTRODUCING A REVOLUTIONARY APPROACH TO MODERATE SLEEP APNEA



Intranasal Positive Expiratory Airway Pressure (INPEAP)

- Patented INPEAP technology
- Targeting 70% of OSA patients with moderate OSA (AHI 14-29)
- Low invasive
- Well tolerated
- Nasal Stenting coupled with nasally delivered EPAP
- Trial underway at Monash Lung and Sleep Dept. Monash Health
- Results later 2015

TARGETING NASAL CONGESTION & WELLNESS OPPORTUNITIES



DECONGESTION

- Proprietary recipe of organic essential oils
- Decongestant
- Targeting use in sport and wellness

ANXIETY

- Relaxation and sleep problems
- Between 2006 - 2011 OTC sleep aids grew by 31%
- Proprietary recipe of organic essential oils

APPETITE MANAGEMENT

- Weight management market
- Direct to consumer program
- Proprietary recipe of organic essential oils

DRUG DELIVERY – MIGRAINE PROOF OF CONCEPT PROGRAM



- **37 million** Americans suffer from migraine
- **< 25% are satisfied** with their existing therapy
- **US\$1.6 billion** - worldwide sales of Imitrex
- **Insitu stable delivery** – new delivery paradigm
- **Acceptance and adoption** established
- Preclinical work showing positive results
- Seeking **Partners**

MICHAEL JOHNSON,
CEO

e. mjohnson@rhinomed.global
t. +61 3 8416 0900
w. rhinomed.global